Sarcoma  >>  Lynparza (olaparib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

16 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lynparza (olaparib) / Merck (MSD), AstraZeneca
NCT01583543: Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma

Checkmark AACR - 2013
Apr 2013 - Apr 2013: AACR - 2013
Completed
2
12
US
Olaparib, AZD 2281
Massachusetts General Hospital
Ewing's Sarcoma
01/14
11/14
2016-004617-28: Does cediranib together with paclitaxel chemotherapy, or cediranib and olaparib, treat advanced endometrial cancer better than paclitaxel chemotherapy?

Not yet recruiting
2
129
Europe
Olaparib (Lynparza), Cediranib, Paclitaxel, AZD2281, AZD2171, Film-coated tablet, Concentrate for solution for infusion, Olaparib (Lynparza)
The University of Manchester, AstraZeneca Ltd
Advanced or recurrent endometrial carcinoma or carcinosarcoma, Endometrial cancer, Diseases [C] - Cancer [C04]
 
 
2018-003779-36: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss.

Not yet recruiting
2
116
Europe
AZD6738, Olaparib (Lynparza), AZD6738, Olaparib (AZD2281), Film-coated tablet, Olaparib (Lynparza)
The Institute of Cancer Research, AstraZeneca UK Limited, Lady Garden Foundation
Relapsed ovarian and endometrial clear cell carcinoma or relapsed other gynaecological cancers (endometriod (ovarian and endometrial), carcinosarcoma (ovarian and endometrial), cerviacal carcinoma (squamous and adenocarcinoma), Relapsed gynaecological cancers of rare subtypes, including clear cell (ovarian/uterus) and carcinosarcoma, cervical and endometrioid type., Diseases [C] - Cancer [C04]
 
 
2019-001316-38: A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Et lægemiddelforsøg af en individualiseret behandlingsstrategi til patienter med undertypen non-clear celle nyrekræft, som har spredt sig

Not yet recruiting
2
30
Europe
Capsule, hard, Film-coated tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tafinlar, Tarceva, Keytruda, Mekinist, Alecensa, Lynparza, Kadcyla, Cabometyx, Xalkori, Ibrance, Tagrisso, Glivec, Sutent, Opdivo
Department of Oncology, Herlev University Hospital, Region Hovedstaden, Roche Denmark
Patients with metastatic non-clear cell or 100% sarcomatoid renal cell carcinoma referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med metastatisk non-clear cell eller 100% sarkomatoid nyrekræft, som henvises med henblik på første linje behandling på onkologisk afdeling, Herlev Hospital, Patients with metastatic kidney cancer with the subtype non-clear cell or 100% sarcomatoid referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med undertypen non-clear cell eller 100% sarkomatoid nyrekræft, som har spredt sig og henvises for at påbegynde den første medicinske kræftbehandling på onkologisk afdeling, Herlev Hospital, Diseases [C] - Cancer [C04]
 
 
NCI protocol 10250, NCT03880019: A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma

Active, not recruiting
2
23
US
Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Core Biopsy, BIOPSY, CORE, CNB, Core Needle, Core Needle Biopsy, Needle Biopsy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
National Cancer Institute (NCI)
Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Uterine Corpus Leiomyosarcoma
08/20
09/24
NCT04076579: Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Active, not recruiting
2
29
US
Olaparib, Trabectedin
University of Michigan Rogel Cancer Center, Janssen Scientific Affairs, LLC, AstraZeneca
Sarcoma, Sarcoma Metastatic
01/23
01/25
COPELIA, NCT03570437: Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?

Active, not recruiting
2
124
Europe
Paclitaxel, L01CD01, Cediranib, AZD2171, 288383-20-0, Olaparib, AZD2281, Lynparza, L01XX46
University of Manchester, AstraZeneca, Cardiff University
Carcinosarcoma, Endometrial Neoplasms
01/23
06/23
NCT03233204: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Active, not recruiting
2
6
US
Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Low Grade Glioma, Malignant Glioma, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Childhood Malignant Germ Cell Tumor, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Rhabdoid Tumor, Wilms Tumor
03/23
09/24
DAPPER, NCT03851614: Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors

Active, not recruiting
2
90
Canada
Durvalumab, Imfinzi, Olaparib, Lynparza, AZD2281, Cediranib, AZD2171
University Health Network, Toronto, AstraZeneca
Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, Leiomyosarcoma
01/25
01/25
NCT05156268: A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

Active, not recruiting
2
26
US
Pembrolizumab, Olaparib
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC
Endometrial Carcinosarcoma
01/25
01/25
NCT04417062: Olaparib With Ceralasertib in Recurrent Osteosarcoma

Recruiting
2
63
US
Olaparib, Lynparza, Ceralasertib, AZD6738
Dana-Farber Cancer Institute, Osteosarcoma Institute, AstraZeneca
Osteosarcoma, Osteosarcoma Recurrent
06/24
06/25
TOMAS2, NCT03838744 / 2018-004497-10: Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.

Active, not recruiting
2
126
Europe
Standard arm: Trabectedin in monotherapy, Trabectedin arm, Experimental arm: Trabectedin + Olaparib, Trabectedin+ Olaparib arm
Italian Sarcoma Group, PharmaMar, AstraZeneca
Advanced Soft Tissue Sarcoma
02/25
02/25
NeoSarc, NCT06116578: Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab

Not yet recruiting
2
36
Europe
Pembrolizumab, WOO (Windows of opportunity), Pembrolizumab and Olaparib, Pembrolizumab adjuvant, Adjuvant
Gustave Roussy, Cancer Campus, Grand Paris, Merck Sharp & Dohme LLC
Cancer
09/26
06/28
MATCH, NCT03155620: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric Screening Trial)

Recruiting
2
2316
Canada, US, RoW
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ensartinib, X-396, Erdafitinib, Balversa, JNJ-42756493, Laboratory Biomarker Analysis, Larotrectinib Sulfate, ARRY 470 Sulfate, LOXO 101 Sulfate, LOXO-101 Sulfate, Vitrakvi, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Mutation Carrier Screening, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Pharmacological Study, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Samotolisib, 2H-Imidazo(4,5-C)quinolin-2-one, 1,3-Dihydro-8-(5-(1-hydroxy-1-methylethyl)-3-pyridinyl)-1-((2S)-2-methoxypropyl)-3-methyl-, LY 3023414, LY-3023414, LY3023414, WHO 10889, Selpercatinib, LOXO-292, RET Kinase Inhibitor LOXO-292, Retevmo, Retsevmo, WHO 10967, Selumetinib Sulfate, AZD-6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulphate, Koselugo, Selumetinib Sulphate, Tazemetostat, E7438, EPZ-6438, EPZ6438, Tipifarnib, R115777, Zarnestra, Ulixertinib, BVD-523, VRT752271, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
09/27
09/27
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
NCT03924245: Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Terminated
1/2
3
US
Entinostat, Olaparib
Vanderbilt-Ingram Cancer Center, AstraZeneca, Syndax Pharmaceuticals
Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
02/22
02/22

Download Options